![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260722_Arrowhead_Image-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Arrowhead Pharmaceuticals<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Results (Phase 3)<\/p>\n Modality<\/strong><\/p>\n RNA Interference (Liver-Targeted siRNA)<\/p>\n Asset<\/strong><\/p>\n Plozasiran (TRiM Platform)<\/p>\n Target<\/strong><\/p>\n APOC3 (Apolipoprotein C-III)<\/p>\n Disease Area<\/strong><\/p>\n Severe Hypertriglyceridemia \/ Acute Pancreatitis Prevention<\/p>\n Arrowhead’s plozasiran met the primary endpoint and every prespecified secondary endpoint in the Phase 3 SHASTA-3 and SHASTA-4 trials. Quarterly 25 mg dosing reduced median triglycerides by 79% and 81% at Month 12 and cut cumulative acute-pancreatitis events by 78% in a pooled analysis, with no events in the highest-risk treated subgroup. The results support a U.S. supplemental filing before year-end and strengthen RNA interference as a chronic cardiometabolic modality, although full event counts and detailed safety data await presentation.<\/p>\n Approximately 750 adults with triglycerides above 500 mg\/dL were randomized across two global, double-blind, placebo-controlled studies to receive plozasiran 25 mg or placebo once every three months. Both trials met the Month 12 triglyceride endpoint and all prespecified secondary endpoints.<\/p>\n Median triglyceride reductions were 79% in SHASTA-3 and 81% in SHASTA-4, compared with approximately 27% for placebo. In the prespecified pooled analysis, plozasiran reduced cumulative acute-pancreatitis events by 78% and significantly reduced both the proportion of patients with an event and the total event rate.<\/p>\n In patients with triglycerides above 880 mg\/dL and a prior pancreatitis history, the company reported a 100% reduction in events. No new safety signals, thrombocytopenia signal, hypersensitivity, clinically meaningful liver-enzyme imbalance, or increase in liver fat was reported. Detailed data are scheduled for the European Society of Cardiology Congress on August 30.<\/p>\n Triglyceride lowering is an accepted pharmacodynamic measure, but prevention of acute pancreatitis is the outcome that most directly changes the value proposition in severe disease. Replication across two trials and a prespecified pooled event analysis make the signal more credible than a single-study biomarker result.<\/p>\n The 100% reduction in the highest-risk subgroup is striking but could be based on a small event count. Absolute events, exposure time, confidence intervals, adjudication procedures, and subgroup size are required before estimating the precision or durability of the effect.<\/p>\n Plozasiran is a liver-targeted small interfering RNA that uses the endogenous RNA-induced silencing complex to degrade APOC3 messenger RNA. Lower APOC3 production accelerates clearance of triglyceride-rich lipoproteins and reduces circulating chylomicron burden.<\/p>\n Quarterly self-administration converts durable gene silencing into a practical chronic-treatment schedule. The data reinforce the liver as a validated entry point for RNAi and show that the modality can compete in broad metabolic populations, not only ultra-rare genetic disease.<\/p>\n Plozasiran is already approved in multiple regions for familial chylomicronemia syndrome. Arrowhead plans to use SHASTA-3, SHASTA-4, and MUIR-3 for expansion into the much larger severe-hypertriglyceridemia population, beginning with a U.S. supplemental application before the end of 2026.<\/p>\n Commercial differentiation will rest on pancreatitis prevention, quarterly convenience, liver safety, and positioning against oral lipid medicines and APOC3-targeting competitors. Broader use will also require payer criteria that identify patients at sufficient pancreatitis risk.<\/p>\n APOC3 is emerging as one of the strongest genetically and clinically validated targets in triglyceride biology. A clinical-event benefit raises the evidence bar for competing antisense and RNAi programs and may shift development toward prevention of pancreatitis rather than lipid change alone.<\/p>\n The program also validates Arrowhead’s TRiM delivery platform and its ability to move from rare-disease launch to larger-market lifecycle expansion. Execution now depends on filing quality, manufacturing scale, and detailed presentation of the pooled endpoint.<\/p>\n Severe hypertriglyceridemia is generally defined by triglycerides above 500 mg\/dL and becomes particularly dangerous as chylomicrons accumulate. Patients can experience recurrent acute pancreatitis, hospitalization, organ complications, and increased cardiovascular risk. Existing diet and drug approaches may not sustain levels below risk thresholds.<\/p>\n Arrowhead develops RNA-interference medicines using its targeted RNAi molecule (TRiM) platform. Plozasiran silences hepatic APOC3, a protein that delays breakdown and clearance of triglyceride-rich particles. Reducing APOC3 lowers triglycerides and is intended to prevent pancreatitis driven by chylomicron excess.<\/p>\n This is a high-importance RNA-modality signal because it connects deep target knockdown to a hard, clinically consequential endpoint across two pivotal trials. The result strengthens both plozasiran’s expansion case and the broader thesis that infrequent liver-directed RNAi can treat common chronic disease.<\/p>\n The topline should be viewed as highly encouraging but not fully characterized. The ESC presentation must confirm absolute pancreatitis events, consistency between trials, exposure-adjusted analyses, and long-term hepatic and metabolic safety before the magnitude can be considered definitive.<\/p>\n Signal strength:<\/strong> 5\/5 \u2014 High. Importance:<\/strong> High \u2014 the program replicated large lipid effects and reported a statistically significant pancreatitis reduction in a population with limited preventive options. Confidence:<\/strong> Medium-High \u2014 two randomized Phase 3 trials support the direction of effect, but confidence in its precise magnitude is constrained until complete event and safety data are presented.<\/p>\n","protected":false},"excerpt":{"rendered":" Arrowhead’s plozasiran met the primary endpoint and every prespecified secondary endpoint in the Phase 3 SHASTA-3 and SHASTA-4 trials. Quarterly 25 mg dosing reduced median triglycerides by 79% and 81% at Month 12 and…<\/p>\n","protected":false},"author":1,"featured_media":2098,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[162,163],"class_list":["post-2086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-arrowhead-pharmaceuticals","tag-hypertriglyceridemia"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2086"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2086\/revisions"}],"predecessor-version":[{"id":2099,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2086\/revisions\/2099"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2098"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Clinical Interpretation<\/h4>\n
Mechanism and Modality<\/h4>\n
Regulatory and Commercial Implications<\/h4>\n
Competitive Read-Through<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n